The University of Chicago Header Logo

Connection

Olufunmilayo Olopade to Humans

This is a "connection" page, showing publications Olufunmilayo Olopade has written about Humans.
Connection Strength

3.153
  1. Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer. JAMA Netw Open. 2023 Dec 01; 6(12):e2349646.
    View in: PubMed
    Score: 0.031
  2. Unawareness of breast cancer family history among African women. Pan Afr Med J. 2023; 45:188.
    View in: PubMed
    Score: 0.030
  3. Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations. Breast Cancer Res. 2023 05 25; 25(1):58.
    View in: PubMed
    Score: 0.030
  4. Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer. JAMA Netw Open. 2023 03 01; 6(3):e233329.
    View in: PubMed
    Score: 0.029
  5. Cancer Genetic Services in a Low- to Middle-Income Country: Cross-Sectional Survey Assessing Willingness to Undergo and Pay for Germline Genetic Testing. JCO Glob Oncol. 2023 02; 9:e2100140.
    View in: PubMed
    Score: 0.029
  6. An enhancer variant associated with breast cancer susceptibility in Black women regulates TNFSF10 expression and antitumor immunity in triple-negative breast cancer. Hum Mol Genet. 2023 01 01; 32(1):139-150.
    View in: PubMed
    Score: 0.029
  7. Subtype-specific expression of MELK is partly due to copy number alterations in breast cancer. PLoS One. 2022; 17(6):e0268693.
    View in: PubMed
    Score: 0.028
  8. Oncology Training Needs Assessment Among Health Care Professionals in Nigeria. JCO Glob Oncol. 2022 05; 8:e2200017.
    View in: PubMed
    Score: 0.028
  9. Mutational spectrum of breast cancer susceptibility genes among women ascertained in a cancer risk clinic in Northeast Brazil. Breast Cancer Res Treat. 2022 Jun; 193(2):485-494.
    View in: PubMed
    Score: 0.028
  10. Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes. Nat Commun. 2021 11 26; 12(1):6946.
    View in: PubMed
    Score: 0.027
  11. Precision oncology: Directing genomics and pharmacogenomics toward reducing cancer inequities. Cancer Cell. 2021 06 14; 39(6):730-733.
    View in: PubMed
    Score: 0.026
  12. Black Lives Matter Worldwide: Retooling Precision Oncology for True Equity of Cancer Care. Cell Rep Med. 2020 08 25; 1(5):100079.
    View in: PubMed
    Score: 0.025
  13. Implementing oncology clinical trials in Nigeria: a model for capacity building. BMC Health Serv Res. 2020 Aug 03; 20(1):713.
    View in: PubMed
    Score: 0.025
  14. Evaluating the Effect of Medicaid Expansion on Black/White Breast Cancer Mortality Disparities: A Difference-in-Difference Analysis. JCO Glob Oncol. 2020 07; 6:1178-1183.
    View in: PubMed
    Score: 0.024
  15. Traditional medicine usage among adult women in Ibadan, Nigeria: a cross-sectional study. BMC Complement Med Ther. 2020 Mar 20; 20(1):93.
    View in: PubMed
    Score: 0.024
  16. Infrastructural Challenges Lead to Delay of Curative Radiotherapy in Nigeria. JCO Glob Oncol. 2020 02; 6:269-276.
    View in: PubMed
    Score: 0.024
  17. USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan. JAMA Netw Open. 2019 08 02; 2(8):e1910142.
    View in: PubMed
    Score: 0.023
  18. Radiogenomics of breast cancer using dynamic contrast enhanced MRI and gene expression profiling. Cancer Imaging. 2019 Jul 15; 19(1):48.
    View in: PubMed
    Score: 0.023
  19. Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria. Int J Cancer. 2019 12 15; 145(12):3321-3333.
    View in: PubMed
    Score: 0.023
  20. The Time for Mainstreaming Germline Testing for Patients With Breast Cancer Is Now. J Clin Oncol. 2019 08 20; 37(24):2177-2178.
    View in: PubMed
    Score: 0.023
  21. Inhibition of Copper Transport Induces Apoptosis in Triple-Negative Breast Cancer Cells and Suppresses Tumor Angiogenesis. Mol Cancer Ther. 2019 05; 18(5):873-885.
    View in: PubMed
    Score: 0.022
  22. LncRNA BLAT1 is Upregulated in Basal-like Breast Cancer through Epigenetic Modifications. Sci Rep. 2018 10 22; 8(1):15572.
    View in: PubMed
    Score: 0.022
  23. Genetic Ancestry May Influence the Evolutionary Trajectory of Cancers. Cancer Cell. 2018 10 08; 34(4):529-530.
    View in: PubMed
    Score: 0.022
  24. Mutations in context: implications of BRCA testing in diverse populations. Fam Cancer. 2018 10; 17(4):471-483.
    View in: PubMed
    Score: 0.022
  25. Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk. Fam Cancer. 2018 10; 17(4):495-505.
    View in: PubMed
    Score: 0.022
  26. Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers. Clin Cancer Res. 2019 03 15; 25(6):1786-1794.
    View in: PubMed
    Score: 0.022
  27. Inherited Breast Cancer in Nigerian Women. J Clin Oncol. 2018 10 01; 36(28):2820-2825.
    View in: PubMed
    Score: 0.022
  28. Knowledge of Genetic Counseling Among Patients With Breast Cancer and Their Relatives at a Nigerian Teaching Hospital. J Glob Oncol. 2018 07; 4:1-8.
    View in: PubMed
    Score: 0.021
  29. Cancer Susceptibility Genetic Testing in a High-Risk Cohort of Urban Ashkenazi Jewish Individuals. J Genet Couns. 2018 12; 27(6):1405-1410.
    View in: PubMed
    Score: 0.021
  30. Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening-Reply. JAMA Oncol. 2018 06 01; 4(6):883-884.
    View in: PubMed
    Score: 0.021
  31. Breast Cancer Genetics Knowledge and Testing Intentions among Nigerian Professional Women. J Genet Couns. 2018 08; 27(4):863-873.
    View in: PubMed
    Score: 0.021
  32. Genetic and Epigenetic Regulation of TOX3 Expression in Breast Cancer. PLoS One. 2016; 11(11):e0165559.
    View in: PubMed
    Score: 0.019
  33. Identification of a circulating microRNA signature to distinguish recurrence in breast cancer patients. Oncotarget. 2016 08 23; 7(34):55231-55248.
    View in: PubMed
    Score: 0.019
  34. Building local capacity for genomics research in Africa: recommendations from analysis of publications in Sub-Saharan Africa from 2004 to 2013. Glob Health Action. 2016; 9:31026.
    View in: PubMed
    Score: 0.018
  35. Long-Term Disease-Free Survival in a Young Patient With Hormone Receptor-Positive Breast Cancer and Oligometastatic Disease in the Brain. Clin Breast Cancer. 2016 Jun; 16(3):e61-3.
    View in: PubMed
    Score: 0.018
  36. A perfect storm: How tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change. CA Cancer J Clin. 2015 May-Jun; 65(3):221-38.
    View in: PubMed
    Score: 0.017
  37. Breast cancer risk after full-term pregnancies among African women from Nigeria, Cameroon, and Uganda. Cancer. 2015 Jul 01; 121(13):2237-43.
    View in: PubMed
    Score: 0.017
  38. ß-catenin regulates c-Myc and CDKN1A expression in breast cancer cells. Mol Carcinog. 2016 May; 55(5):431-9.
    View in: PubMed
    Score: 0.017
  39. Race, ethnicity, and the diagnosis of breast cancer. JAMA. 2015 Jan 13; 313(2):141-2.
    View in: PubMed
    Score: 0.017
  40. Social barriers to diagnosis and treatment of breast cancer in patients presenting at a teaching hospital in Ibadan, Nigeria. Glob Public Health. 2015; 10(3):331-44.
    View in: PubMed
    Score: 0.017
  41. Inherited predisposition to breast cancer among African American women. Breast Cancer Res Treat. 2015 Jan; 149(1):31-9.
    View in: PubMed
    Score: 0.017
  42. Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report. Clin Breast Cancer. 2015 Apr; 15(2):e155-8.
    View in: PubMed
    Score: 0.016
  43. Tumor genome analysis includes germline genome: are we ready for surprises? Int J Cancer. 2015 Apr 01; 136(7):1559-67.
    View in: PubMed
    Score: 0.016
  44. Obituary: Janet Davison Rowley 1925-2013. Cell. 2014 Jan 30; 156(3):390-1.
    View in: PubMed
    Score: 0.016
  45. Use of Web-based training for quality improvement between a field immunohistochemistry laboratory in Nigeria and its United States-based partner institution. Ann Diagn Pathol. 2013 Dec; 17(6):526-30.
    View in: PubMed
    Score: 0.015
  46. Neo-adjuvant capecitabine chemotherapy in women with newly diagnosed locally advanced breast cancer in a resource-poor setting (Nigeria): efficacy and safety in a phase II feasibility study. Breast J. 2013 Sep-Oct; 19(5):470-7.
    View in: PubMed
    Score: 0.015
  47. The use of allelic imbalance to ascertain cis-regulation for human UGT2B7 in vivo. Eur J Clin Pharmacol. 2013 Sep; 69(9):1733-5.
    View in: PubMed
    Score: 0.015
  48. The role of tumor-associated macrophages in breast cancer progression (review). Int J Oncol. 2013 Jul; 43(1):5-12.
    View in: PubMed
    Score: 0.015
  49. Expression and sub-cellular localization of an epigenetic regulator, co-activator arginine methyltransferase 1 (CARM1), is associated with specific breast cancer subtypes and ethnicity. Mol Cancer. 2013 May 10; 12(1):40.
    View in: PubMed
    Score: 0.015
  50. Level of awareness of mammography among women attending outpatient clinics in a teaching hospital in Ibadan, South-West Nigeria. BMC Public Health. 2013 Jan 16; 13:40.
    View in: PubMed
    Score: 0.015
  51. Resistance to trastuzumab in HER2-positive mucinous invasive ductal breast carcinoma. Clin Breast Cancer. 2013 Apr; 13(2):156-8.
    View in: PubMed
    Score: 0.015
  52. Genetic determinants of breast cancer risk: a review of current literature and issues pertaining to clinical application. Breast J. 2012 Sep; 18(5):436-42.
    View in: PubMed
    Score: 0.014
  53. Hidden dangers: a cryptic exon disrupts BRCA2 mRNA. Clin Cancer Res. 2012 Sep 15; 18(18):4865-7.
    View in: PubMed
    Score: 0.014
  54. Protective effect of longstanding lactation and reproductive factors: a case-control study in North Tanzania. Breast Cancer Res Treat. 2012 Aug; 134(3):1349-51.
    View in: PubMed
    Score: 0.014
  55. Microsatellites in the estrogen receptor (ESR1, ESR2) and androgen receptor (AR) genes and breast cancer risk in African American and Nigerian women. PLoS One. 2012; 7(7):e40494.
    View in: PubMed
    Score: 0.014
  56. Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry. Breast Cancer Res Treat. 2012 Jul; 134(2):889-94.
    View in: PubMed
    Score: 0.014
  57. Body fat distribution and breast cancer risk: findings from the Nigerian breast cancer study. Cancer Causes Control. 2012 Apr; 23(4):565-74.
    View in: PubMed
    Score: 0.014
  58. Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis. 2012 Apr; 33(4):835-40.
    View in: PubMed
    Score: 0.014
  59. High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. Int J Cancer. 2012 Sep 01; 131(5):1114-23.
    View in: PubMed
    Score: 0.014
  60. Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. Clin Cancer Res. 2012 Jan 15; 18(2):350-9.
    View in: PubMed
    Score: 0.013
  61. Race and subset analyses in clinical trials: time to get serious about data integration. J Natl Cancer Inst. 2011 Oct 19; 103(20):1486-8.
    View in: PubMed
    Score: 0.013
  62. Novel germline PALB2 truncating mutations in African American breast cancer patients. Cancer. 2012 Mar 01; 118(5):1362-70.
    View in: PubMed
    Score: 0.013
  63. c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells. BMC Cancer. 2011 Jun 13; 11:246.
    View in: PubMed
    Score: 0.013
  64. CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine. Semin Oncol. 2011 Apr; 38(2):263-73.
    View in: PubMed
    Score: 0.013
  65. Is screening with magnetic resonance imaging in BRCA mutation carriers a safe and effective alternative to prophylactic mastectomy? J Clin Oncol. 2011 May 01; 29(13):1652-4.
    View in: PubMed
    Score: 0.013
  66. Concordance in histological and biological parameters between first and second primary breast cancers. Cancer. 2011 Mar 01; 117(5):907-15.
    View in: PubMed
    Score: 0.012
  67. Case-control study of body size and breast cancer risk in Nigerian women. Am J Epidemiol. 2010 Sep 15; 172(6):682-90.
    View in: PubMed
    Score: 0.012
  68. Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer. Breast Cancer Res Treat. 2010 Dec; 124(3):857-61.
    View in: PubMed
    Score: 0.012
  69. Searching for large genomic rearrangements of the BRCA1 gene in a Nigerian population. Breast Cancer Res Treat. 2010 Nov; 124(2):573-7.
    View in: PubMed
    Score: 0.012
  70. Interpretation of genome-wide association study results. Oncology (Williston Park). 2010 Jun; 24(7):643, 646.
    View in: PubMed
    Score: 0.012
  71. The importance of transdisciplinary collaborations for understanding and resolving health disparities. Soc Work Public Health. 2010 May; 25(3):408-22.
    View in: PubMed
    Score: 0.012
  72. Risk assessment and genetic testing for ovarian cancer. AJR Am J Roentgenol. 2010 Feb; 194(2):309-10.
    View in: PubMed
    Score: 0.012
  73. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? Cancer J. 2010 Jan-Feb; 16(1):23-32.
    View in: PubMed
    Score: 0.012
  74. Estrogen deprivation therapy and colon cancer risk in breast cancer patients. Breast J. 2010 Jan-Feb; 16(1):110-2.
    View in: PubMed
    Score: 0.012
  75. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009 Sep 20; 27(27):4515-21.
    View in: PubMed
    Score: 0.012
  76. CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors. Breast Cancer Res Treat. 2010 Apr; 120(3):593-601.
    View in: PubMed
    Score: 0.011
  77. Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States. J Clin Oncol. 2009 Mar 10; 27(8):1184-90.
    View in: PubMed
    Score: 0.011
  78. Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res. 2008 Dec 15; 14(24):7988-99.
    View in: PubMed
    Score: 0.011
  79. MYC in breast tumor progression. Expert Rev Anticancer Ther. 2008 Oct; 8(10):1689-98.
    View in: PubMed
    Score: 0.011
  80. Translational integrity and continuity: personalized biomedical data integration. J Biomed Inform. 2009 Feb; 42(1):100-12.
    View in: PubMed
    Score: 0.011
  81. Evidence for an ancient BRCA1 mutation in breast cancer patients of Yoruban ancestry. Fam Cancer. 2009; 8(1):15-22.
    View in: PubMed
    Score: 0.011
  82. Family history of pancreatic cancer in a high-risk cancer clinic: implications for risk assessment. J Genet Couns. 2008 Aug; 17(4):365-72.
    View in: PubMed
    Score: 0.011
  83. Targeting health disparities: a model linking upstream determinants to downstream interventions. Health Aff (Millwood). 2008 Mar-Apr; 27(2):339-49.
    View in: PubMed
    Score: 0.010
  84. Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet Med. 2008 Mar; 10(3):161-166.
    View in: PubMed
    Score: 0.010
  85. Parity and breastfeeding are protective against breast cancer in Nigerian women. Br J Cancer. 2008 Mar 11; 98(5):992-6.
    View in: PubMed
    Score: 0.010
  86. Genetic testing in diverse populations: are researchers doing enough to get out the correct message? JAMA. 2007 Dec 26; 298(24):2910-1.
    View in: PubMed
    Score: 0.010
  87. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer. 2007 Dec; 7(12):937-48.
    View in: PubMed
    Score: 0.010
  88. Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers. Breast Cancer Res Treat. 2008 Sep; 111(1):113-20.
    View in: PubMed
    Score: 0.010
  89. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and breast cancer risk in Africans. Breast Cancer Res Treat. 2008 Jul; 110(2):367-76.
    View in: PubMed
    Score: 0.010
  90. Genetic susceptibility to breast cancer. Rev Endocr Metab Disord. 2007 Sep; 8(3):255-67.
    View in: PubMed
    Score: 0.010
  91. UDP-Glucuronosyltransferase 1A1 gene polymorphisms and total bilirubin levels in an ethnically diverse cohort of women. Drug Metab Dispos. 2007 Aug; 35(8):1254-61.
    View in: PubMed
    Score: 0.010
  92. Correlates of depressive symptoms among women seeking cancer genetic counseling and risk assessment at a high-risk cancer clinic. J Genet Couns. 2006 Aug; 15(4):267-76.
    View in: PubMed
    Score: 0.009
  93. Disparities in cancer care: a worldwide perspective and roadmap for change. J Clin Oncol. 2006 May 10; 24(14):2135-6.
    View in: PubMed
    Score: 0.009
  94. Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J Clin Oncol. 2006 May 10; 24(14):2179-87.
    View in: PubMed
    Score: 0.009
  95. Disparities in genetic testing: thinking outside the BRCA box. J Clin Oncol. 2006 May 10; 24(14):2197-203.
    View in: PubMed
    Score: 0.009
  96. Primary structure-based function characterization of BRCT domain replicates in BRCA1. Biochem Biophys Res Commun. 2006 Jun 23; 345(1):188-96.
    View in: PubMed
    Score: 0.009
  97. Using genetic analysis to individualize preventive measures for breast and ovarian cancers. Nat Clin Pract Oncol. 2006 Apr; 3(4):182-3.
    View in: PubMed
    Score: 0.009
  98. BRCA2 mutation and the risk of hematologic malignancy. Leuk Lymphoma. 2006 Apr; 47(4):765-7.
    View in: PubMed
    Score: 0.009
  99. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res. 2005 Dec 01; 65(23):10692-9.
    View in: PubMed
    Score: 0.009
  100. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA. 2005 Oct 19; 294(15):1925-33.
    View in: PubMed
    Score: 0.009
  101. Racial and ethnic disparities in breast cancer: a multilevel perspective. Med Clin North Am. 2005 Jul; 89(4):753-70.
    View in: PubMed
    Score: 0.009
  102. Colorectal cancer and race: understanding the differences in outcomes between African Americans and whites. Med Clin North Am. 2005 Jul; 89(4):771-93.
    View in: PubMed
    Score: 0.009
  103. Confronting genetic testing disparities: knowledge is power. JAMA. 2005 Apr 13; 293(14):1783-5.
    View in: PubMed
    Score: 0.009
  104. Complete allelic analysis of BRCA1 and BRCA2 variants in young Nigerian breast cancer patients. J Med Genet. 2005 Mar; 42(3):276-81.
    View in: PubMed
    Score: 0.008
  105. Breast cancer and race: a rising tide does not lift all boats equally. Perspect Biol Med. 2005; 48(1 Suppl):S166-75.
    View in: PubMed
    Score: 0.008
  106. Benign breast disease and breast cancer risk in African women: a case-control study. Cancer Causes Control. 2024 May; 35(5):787-798.
    View in: PubMed
    Score: 0.008
  107. Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations. Breast J. 2004 Jan-Feb; 10 Suppl 1:S5-9.
    View in: PubMed
    Score: 0.008
  108. Validation of the RSClin risk calculator in the National Cancer Data Base. Cancer. 2024 Apr 15; 130(8):1210-1220.
    View in: PubMed
    Score: 0.008
  109. Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a BRCA1 or BRCA2 Mutation. Cancer Res Commun. 2023 11 28; 3(11):2420-2429.
    View in: PubMed
    Score: 0.008
  110. Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial: A Randomized Clinical Trial. JAMA Oncol. 2023 Nov 01; 9(11):1547-1555.
    View in: PubMed
    Score: 0.008
  111. Racial/Ethnic Disparities in Telemedicine Utilization and Satisfaction Among Breast Cancer Patients During the COVID-19 Pandemic: A Mixed-Methods Analysis. Telemed J E Health. 2024 Mar; 30(3):651-663.
    View in: PubMed
    Score: 0.008
  112. Breast Cancer Germline Genetic Counseling and Testing for Populations of African Heritage Globally: A Scoping Review on Research, Practice, and Bioethical Considerations. JCO Glob Oncol. 2023 Sep; 9:e2300154.
    View in: PubMed
    Score: 0.008
  113. Direct-to-consumer marketing of genetic tests for cancer: buyer beware. J Clin Oncol. 2003 Sep 01; 21(17):3191-3.
    View in: PubMed
    Score: 0.008
  114. Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation. Breast Cancer Res Treat. 2023 Sep; 201(2):257-264.
    View in: PubMed
    Score: 0.008
  115. Obesity and height in urban Nigerian women with breast cancer. Ann Epidemiol. 2003 Jul; 13(6):455-61.
    View in: PubMed
    Score: 0.008
  116. A joint transcriptome-wide association study across multiple tissues identifies candidate breast cancer susceptibility genes. Am J Hum Genet. 2023 06 01; 110(6):950-962.
    View in: PubMed
    Score: 0.007
  117. FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell. 2003 May; 3(5):417-20.
    View in: PubMed
    Score: 0.007
  118. Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database. JAMA Oncol. 2023 04 01; 9(4):500-510.
    View in: PubMed
    Score: 0.007
  119. Response to Treatment, Racial and Ethnic Disparity, and Survival in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy in the US. JAMA Netw Open. 2023 03 01; 6(3):e235834.
    View in: PubMed
    Score: 0.007
  120. Racial differences in genetic factors associated with breast cancer. Cancer Metastasis Rev. 2003 Mar; 22(1):47-53.
    View in: PubMed
    Score: 0.007
  121. A metabolome-wide case-control study of african american breast cancer patients. BMC Cancer. 2023 Feb 23; 23(1):183.
    View in: PubMed
    Score: 0.007
  122. The optimization of postoperative radiotherapy in de novo stage IV breast cancer: evidence from real-world data to personalize treatment decisions. Sci Rep. 2023 02 18; 13(1):2880.
    View in: PubMed
    Score: 0.007
  123. Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry. Genome Med. 2023 01 26; 15(1):7.
    View in: PubMed
    Score: 0.007
  124. Validation of the Nigerian Breast Cancer Study Model for Predicting Individual Breast Cancer Risk in Cameroon and Uganda. Cancer Epidemiol Biomarkers Prev. 2023 01 09; 32(1):98-104.
    View in: PubMed
    Score: 0.007
  125. Breast cancer genetics in African Americans. Cancer. 2003 Jan 01; 97(1 Suppl):236-45.
    View in: PubMed
    Score: 0.007
  126. Demographic and Clinical Characteristics Associated With Familiarity, Interest, and Use of Integrative Therapies Among Patients With Breast Cancer. Integr Cancer Ther. 2023 Jan-Dec; 22:15347354231185122.
    View in: PubMed
    Score: 0.007
  127. The risks of cancer in older women with BRCA pathogenic variants: How far have we come? Cancer. 2023 03 15; 129(6):901-907.
    View in: PubMed
    Score: 0.007
  128. Polygenic risk scores for prediction of breast cancer risk in women of African ancestry: a cross-ancestry approach. Hum Mol Genet. 2022 09 10; 31(18):3133-3143.
    View in: PubMed
    Score: 0.007
  129. BRCA2 T2722R is a deleterious allele that causes exon skipping. Am J Hum Genet. 2002 Sep; 71(3):625-31.
    View in: PubMed
    Score: 0.007
  130. Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal. Cancer Epidemiol Biomarkers Prev. 2022 07 01; 31(7):1351-1358.
    View in: PubMed
    Score: 0.007
  131. Differences in somatic TP53 mutation type in breast tumors by race and receptor status. Breast Cancer Res Treat. 2022 Apr; 192(3):639-648.
    View in: PubMed
    Score: 0.007
  132. Detection of germline variants in Brazilian breast cancer patients using multigene panel testing. Sci Rep. 2022 03 09; 12(1):4190.
    View in: PubMed
    Score: 0.007
  133. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res. 2002 Mar 01; 62(5):1481-8.
    View in: PubMed
    Score: 0.007
  134. Polygenic risk modeling for prediction of epithelial ovarian cancer risk. Eur J Hum Genet. 2022 03; 30(3):349-362.
    View in: PubMed
    Score: 0.007
  135. Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study. Appl Immunohistochem Mol Morphol. 2022 01 01; 30(1):27-35.
    View in: PubMed
    Score: 0.007
  136. Associations between age of menarche and genetic variation in women of African descent: genome-wide association study and polygenic score analysis. J Epidemiol Community Health. 2022 04; 76(4):411-417.
    View in: PubMed
    Score: 0.007
  137. Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center. Ann Surg Oncol. 2022 Feb; 29(2):1423-1432.
    View in: PubMed
    Score: 0.007
  138. Evaluating Polygenic Risk Scores for Breast Cancer in Women of African Ancestry. J Natl Cancer Inst. 2021 09 04; 113(9):1168-1176.
    View in: PubMed
    Score: 0.007
  139. Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiol Biomarkers Prev. 2021 11; 30(11):2038-2043.
    View in: PubMed
    Score: 0.007
  140. The impact of coronavirus disease 2019 on the quality of life and treatment disruption of patients with breast cancer in a multiethnic cohort. Cancer. 2021 11 01; 127(21):4072-4080.
    View in: PubMed
    Score: 0.007
  141. The impact of site-specific digital histology signatures on deep learning model accuracy and bias. Nat Commun. 2021 07 20; 12(1):4423.
    View in: PubMed
    Score: 0.007
  142. Cross-ancestry GWAS meta-analysis identifies six breast cancer loci in African and European ancestry women. Nat Commun. 2021 07 07; 12(1):4198.
    View in: PubMed
    Score: 0.007
  143. Cancer genetics in oncology practice. Ann Oncol. 2001 Jul; 12(7):895-908.
    View in: PubMed
    Score: 0.007
  144. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001 Jun 28; 344(26):2028-9.
    View in: PubMed
    Score: 0.007
  145. Alterations of the 9p21 and 9q33 chromosomal bands in clinical bladder cancer specimens by fluorescence in situ hybridization. Clin Cancer Res. 2001 Jun; 7(6):1676-82.
    View in: PubMed
    Score: 0.007
  146. Discovery and fine-mapping of height loci via high-density imputation of GWASs in individuals of African ancestry. Am J Hum Genet. 2021 04 01; 108(4):564-582.
    View in: PubMed
    Score: 0.006
  147. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet. 2001 Mar; 38(3):159-64.
    View in: PubMed
    Score: 0.006
  148. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nat Commun. 2021 02 17; 12(1):1078.
    View in: PubMed
    Score: 0.006
  149. Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients. Breast Cancer Res. 2021 02 04; 23(1):18.
    View in: PubMed
    Score: 0.006
  150. A case of pulmonary toxicity associated with G-CSF and doxorubicin administration. Ann Hematol. 2001 Feb; 80(2):121-3.
    View in: PubMed
    Score: 0.006
  151. The BRCA1 Pseudogene Negatively Regulates Antitumor Responses through Inhibition of Innate Immune Defense Mechanisms. Cancer Res. 2021 03 15; 81(6):1540-1551.
    View in: PubMed
    Score: 0.006
  152. Racial disparities in survival outcomes among breast cancer patients by molecular subtypes. Breast Cancer Res Treat. 2021 Feb; 185(3):841-849.
    View in: PubMed
    Score: 0.006
  153. p50 mono-ubiquitination and interaction with BARD1 regulates cell cycle progression and maintains genome stability. Nat Commun. 2020 10 06; 11(1):5007.
    View in: PubMed
    Score: 0.006
  154. Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol. 2020 12; 159(3):820-826.
    View in: PubMed
    Score: 0.006
  155. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 09 01; 6(9):1355-1362.
    View in: PubMed
    Score: 0.006
  156. Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer. Hum Genet. 2000 Aug; 107(2):186-91.
    View in: PubMed
    Score: 0.006
  157. Protein truncating BRCA1 and BRCA2 mutations in African women with pre-menopausal breast cancer. Hum Genet. 2000 Aug; 107(2):192-4.
    View in: PubMed
    Score: 0.006
  158. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genet Med. 2020 10; 22(10):1653-1666.
    View in: PubMed
    Score: 0.006
  159. Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Sci Rep. 2020 06 16; 10(1):9688.
    View in: PubMed
    Score: 0.006
  160. Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base. Cancer. 2020 09 01; 126(17):4013-4022.
    View in: PubMed
    Score: 0.006
  161. Susceptibility gene for familial acute myeloid leukemia associated with loss of 5q and/or 7q is not localized on the commonly deleted portion of 5q. Genes Chromosomes Cancer. 2000 Jun; 28(2):164-72.
    View in: PubMed
    Score: 0.006
  162. Longitudinal follow-up after telephone disclosure in the randomized COGENT study. Genet Med. 2020 08; 22(8):1401-1406.
    View in: PubMed
    Score: 0.006
  163. Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633.
    View in: PubMed
    Score: 0.006
  164. Care Coordination for Breast Cancer Survivors in Urban Underserved Communities: Will Treatment Summaries and Survivorship Care Plans Be Enough? J Racial Ethn Health Disparities. 2020 06; 7(3):577-583.
    View in: PubMed
    Score: 0.006
  165. Computerized analysis of mammographic parenchymal patterns for breast cancer risk assessment: feature selection. Med Phys. 2000 Jan; 27(1):4-12.
    View in: PubMed
    Score: 0.006
  166. Prevalence of Inherited Mutations in Breast Cancer Predisposition Genes among Women in Uganda and Cameroon. Cancer Epidemiol Biomarkers Prev. 2020 02; 29(2):359-367.
    View in: PubMed
    Score: 0.006
  167. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. J Clin Oncol. 2020 03 01; 38(7):674-685.
    View in: PubMed
    Score: 0.006
  168. Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer. Cancer Res. 2020 02 01; 80(3):394-405.
    View in: PubMed
    Score: 0.006
  169. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Res. 2020 02 01; 80(3):624-638.
    View in: PubMed
    Score: 0.006
  170. Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response. Cell Death Dis. 2019 09 11; 10(9):666.
    View in: PubMed
    Score: 0.006
  171. Breast Cancer Risk-Associated SNPs in the mTOR Promoter Form De Novo KLF5- and ZEB1-Binding Sites that Influence the Cellular Response to Paclitaxel. Mol Cancer Res. 2019 11; 17(11):2244-2256.
    View in: PubMed
    Score: 0.006
  172. Two truncating variants in FANCC and breast cancer risk. Sci Rep. 2019 08 29; 9(1):12524.
    View in: PubMed
    Score: 0.006
  173. Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study. Cancer Med. 2019 09; 8(12):5609-5618.
    View in: PubMed
    Score: 0.006
  174. The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries. Hum Mutat. 2019 11; 40(11):e1-e23.
    View in: PubMed
    Score: 0.006
  175. Causes and remedies for low research productivity among postgraduate scholars and early career researchers on non-communicable diseases in Nigeria. BMC Res Notes. 2019 Jul 15; 12(1):403.
    View in: PubMed
    Score: 0.006
  176. BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. Hum Mutat. 2019 10; 40(10):1781-1796.
    View in: PubMed
    Score: 0.006
  177. N-acetyltransferase 2 enzyme genotype-phenotype discordances in both HIV-negative and HIV-positive Nigerians. Pharmacogenet Genomics. 2019 07; 29(5):106-113.
    View in: PubMed
    Score: 0.006
  178. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2019 07; 121(2):180-192.
    View in: PubMed
    Score: 0.006
  179. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nat Commun. 2019 04 15; 10(1):1741.
    View in: PubMed
    Score: 0.006
  180. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. J Natl Cancer Inst. 2019 04 01; 111(4):350-364.
    View in: PubMed
    Score: 0.006
  181. A response to "Personalised medicine and population health: breast and ovarian cancer". Hum Genet. 2019 Mar; 138(3):287-289.
    View in: PubMed
    Score: 0.006
  182. Association study in African-admixed populations across the Americas recapitulates asthma risk loci in non-African populations. Nat Commun. 2019 02 20; 10(1):880.
    View in: PubMed
    Score: 0.006
  183. Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2019 Jun; 175(2):443-449.
    View in: PubMed
    Score: 0.006
  184. Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. Br J Cancer. 2019 02; 120(4):398-403.
    View in: PubMed
    Score: 0.006
  185. Implementation of a Novel Medical School Multidisciplinary and Interprofessional Oncology Curriculum: a Mixed Method Study. J Cancer Educ. 2019 02; 34(1):50-55.
    View in: PubMed
    Score: 0.006
  186. Shared heritability and functional enrichment across six solid cancers. Nat Commun. 2019 01 25; 10(1):431.
    View in: PubMed
    Score: 0.006
  187. Identification of novel common breast cancer risk variants at the 6q25 locus among Latinas. Breast Cancer Res. 2019 01 14; 21(1):3.
    View in: PubMed
    Score: 0.006
  188. Preferences for in-person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study. Clin Genet. 2019 02; 95(2):293-301.
    View in: PubMed
    Score: 0.005
  189. Assembly of a pan-genome from deep sequencing of 910 humans of African descent. Nat Genet. 2019 01; 51(1):30-35.
    View in: PubMed
    Score: 0.005
  190. Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy? Cancer. 2019 01 15; 125(2):213-222.
    View in: PubMed
    Score: 0.005
  191. HIF-2a promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways. J Exp Clin Cancer Res. 2018 Oct 19; 37(1):256.
    View in: PubMed
    Score: 0.005
  192. Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. Nat Commun. 2018 10 16; 9(1):4181.
    View in: PubMed
    Score: 0.005
  193. A longitudinal study of the prevalence and characteristics of breast disorders detected by clinical breast examination during pregnancy and six months postpartum in Ibadan, Southwestern Nigeria. BMC Womens Health. 2018 09 19; 18(1):152.
    View in: PubMed
    Score: 0.005
  194. Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results. J Natl Cancer Inst. 2018 09 01; 110(9):985-993.
    View in: PubMed
    Score: 0.005
  195. Predisposition testing for inherited breast cancer. Oncology (Williston Park). 1998 Aug; 12(8):1227-41; discussion 1241-2.
    View in: PubMed
    Score: 0.005
  196. A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res. 2018 09 15; 78(18):5419-5430.
    View in: PubMed
    Score: 0.005
  197. CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Cancer Epidemiol Biomarkers Prev. 2018 11; 27(11):1364-1370.
    View in: PubMed
    Score: 0.005
  198. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nat Genet. 2018 07; 50(7):968-978.
    View in: PubMed
    Score: 0.005
  199. Genetic variation in the Hippo pathway and breast cancer risk in women of African ancestry. Mol Carcinog. 2018 10; 57(10):1311-1318.
    View in: PubMed
    Score: 0.005
  200. Genetic testing for susceptibility to cancer. Task Force on Cancer Genetics Education. JAMA. 1998 May 27; 279(20):1612-3.
    View in: PubMed
    Score: 0.005
  201. Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma. Genes Chromosomes Cancer. 1998 May; 22(1):72-8.
    View in: PubMed
    Score: 0.005
  202. Development of a Breast Cancer Risk Prediction Model for Women in Nigeria. Cancer Epidemiol Biomarkers Prev. 2018 06; 27(6):636-643.
    View in: PubMed
    Score: 0.005
  203. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat. 2018 05; 39(5):593-620.
    View in: PubMed
    Score: 0.005
  204. A meta-analysis approach with filtering for identifying gene-level gene-environment interactions. Genet Epidemiol. 2018 07; 42(5):434-446.
    View in: PubMed
    Score: 0.005
  205. Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2018 Jun; 169(3):561-571.
    View in: PubMed
    Score: 0.005
  206. Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst. 2018 02 01; 110(2).
    View in: PubMed
    Score: 0.005
  207. Scaffold-associated regions in the human type I interferon gene cluster on the short arm of chromosome 9. Genomics. 1998 Jan 15; 47(2):217-29.
    View in: PubMed
    Score: 0.005
  208. Population-dependent Intron Retention and DNA Methylation in Breast Cancer. Mol Cancer Res. 2018 03; 16(3):461-469.
    View in: PubMed
    Score: 0.005
  209. Genetic variants demonstrating flip-flop phenomenon and breast cancer risk prediction among women of African ancestry. Breast Cancer Res Treat. 2018 Apr; 168(3):703-712.
    View in: PubMed
    Score: 0.005
  210. Association of Pancreatic Cancer Susceptibility Variants with Risk of Breast Cancer in Women of European and African Ancestry. Cancer Epidemiol Biomarkers Prev. 2018 01; 27(1):116-118.
    View in: PubMed
    Score: 0.005
  211. Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. JAMA Oncol. 2017 12 01; 3(12):1654-1662.
    View in: PubMed
    Score: 0.005
  212. Household air pollution and chronic hypoxia in the placenta of pregnant Nigerian women: A randomized controlled ethanol Cookstove intervention. Sci Total Environ. 2018 Apr 01; 619-620:212-220.
    View in: PubMed
    Score: 0.005
  213. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet. 2017 Dec; 49(12):1767-1778.
    View in: PubMed
    Score: 0.005
  214. Association analysis identifies 65 new breast cancer risk loci. Nature. 2017 11 02; 551(7678):92-94.
    View in: PubMed
    Score: 0.005
  215. Trans-ethnic predicted expression genome-wide association analysis identifies a gene for estrogen receptor-negative breast cancer. PLoS Genet. 2017 Sep; 13(9):e1006727.
    View in: PubMed
    Score: 0.005
  216. Genetic variation in the vitamin D related pathway and breast cancer risk in women of African ancestry in the root consortium. Int J Cancer. 2018 01 01; 142(1):36-43.
    View in: PubMed
    Score: 0.005
  217. Association of breast cancer risk and the mTOR pathway in women of African ancestry in 'The Root' Consortium. Carcinogenesis. 2017 08 01; 38(8):789-796.
    View in: PubMed
    Score: 0.005
  218. Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States. JAMA Oncol. 2017 Jul 01; 3(7):928-935.
    View in: PubMed
    Score: 0.005
  219. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2017 07 01; 109(7).
    View in: PubMed
    Score: 0.005
  220. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J Sci Am. 1997 Jul-Aug; 3(4):230-7.
    View in: PubMed
    Score: 0.005
  221. The Human Genome Project and breast cancer. Womens Health Issues. 1997 Jul-Aug; 7(4):209-14.
    View in: PubMed
    Score: 0.005
  222. Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869.
    View in: PubMed
    Score: 0.005
  223. Household air pollution and angiogenic factors in pregnant Nigerian women: A randomized controlled ethanol cookstove intervention. Sci Total Environ. 2017 Dec 01; 599-600:2175-2181.
    View in: PubMed
    Score: 0.005
  224. Recurrent germ-line BRCA1 mutations in extended African American families with early-onset breast cancer. Am J Hum Genet. 1997 May; 60(5):1233-6.
    View in: PubMed
    Score: 0.005
  225. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J Clin Oncol. 2017 Jul 10; 35(20):2240-2250.
    View in: PubMed
    Score: 0.005
  226. Characterizing Genetic Susceptibility to Breast Cancer in Women of African Ancestry. Cancer Epidemiol Biomarkers Prev. 2017 07; 26(7):1016-1026.
    View in: PubMed
    Score: 0.005
  227. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017 May; 49(5):680-691.
    View in: PubMed
    Score: 0.005
  228. Fast bilateral breast coverage with high spectral and spatial resolution (HiSS) MRI at 3T. J Magn Reson Imaging. 2017 11; 46(5):1341-1348.
    View in: PubMed
    Score: 0.005
  229. Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention. Cancer Prev Res (Phila). 2017 Apr; 10(4):255-266.
    View in: PubMed
    Score: 0.005
  230. Generation of small insert genomic FISH probes with high signal intensity suitable for deletion mapping. Cytogenet Cell Genet. 1997; 76(3-4):202-5.
    View in: PubMed
    Score: 0.005
  231. Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Res. 2016 11 11; 18(1):112.
    View in: PubMed
    Score: 0.005
  232. Genetics in clinical cancer care--the future is now. N Engl J Med. 1996 Nov 07; 335(19):1455-6.
    View in: PubMed
    Score: 0.005
  233. Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for oestrogen receptor negative breast cancer. Hum Mol Genet. 2016 11 01; 25(21):4835-4846.
    View in: PubMed
    Score: 0.005
  234. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Res Treat. 2017 01; 161(1):117-134.
    View in: PubMed
    Score: 0.005
  235. A continuum of admixture in the Western Hemisphere revealed by the African Diaspora genome. Nat Commun. 2016 10 11; 7:12522.
    View in: PubMed
    Score: 0.005
  236. Genetic testing of families with hereditary diseases. JAMA. 1996 Oct 09; 276(14):1138-9; author reply 1140.
    View in: PubMed
    Score: 0.005
  237. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis. Medicine (Baltimore). 2016 Oct; 95(40):e4975.
    View in: PubMed
    Score: 0.005
  238. Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine. Blood. 1996 Sep 15; 88(6):2354-5.
    View in: PubMed
    Score: 0.005
  239. Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2. Breast Cancer Res Treat. 2016 11; 160(1):121-129.
    View in: PubMed
    Score: 0.005
  240. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun. 2016 09 07; 7:12675.
    View in: PubMed
    Score: 0.005
  241. Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS One. 2016; 11(7):e0158801.
    View in: PubMed
    Score: 0.005
  242. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34.
    View in: PubMed
    Score: 0.005
  243. Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry. Hum Genet. 2016 10; 135(10):1145-59.
    View in: PubMed
    Score: 0.005
  244. Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res. 2016 06 21; 18(1):64.
    View in: PubMed
    Score: 0.005
  245. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nat Commun. 2016 04 27; 7:11375.
    View in: PubMed
    Score: 0.005
  246. Naturally occurring BRCA2 alternative mRNA splicing events in clinically relevant samples. J Med Genet. 2016 08; 53(8):548-58.
    View in: PubMed
    Score: 0.005
  247. Familial myeloid leukemia associated with loss of the long arm of chromosome 5. Leukemia. 1996 Apr; 10(4):669-74.
    View in: PubMed
    Score: 0.005
  248. An Evaluation of Psychosocial and Religious Belief Differences in a Diverse Racial and Socioeconomic Urban Cancer Population. J Racial Ethn Health Disparities. 2017 04; 4(2):140-148.
    View in: PubMed
    Score: 0.005
  249. Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect. Cancer. 2016 06 15; 122(12):1913-20.
    View in: PubMed
    Score: 0.005
  250. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nat Genet. 2016 Apr; 48(4):374-86.
    View in: PubMed
    Score: 0.005
  251. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2016 Feb 09; 18(1):15.
    View in: PubMed
    Score: 0.005
  252. The Breast-Thyroid Cancer Link: A Systematic Review and Meta-analysis. Cancer Epidemiol Biomarkers Prev. 2016 Feb; 25(2):231-8.
    View in: PubMed
    Score: 0.005
  253. Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy. PLoS One. 2016; 11(1):e0147145.
    View in: PubMed
    Score: 0.004
  254. The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes. Urol Res. 1996; 24(4):239-44.
    View in: PubMed
    Score: 0.004
  255. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer. 2016 Jan 15; 122(2):304-11.
    View in: PubMed
    Score: 0.004
  256. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst. 2016 Feb; 108(2).
    View in: PubMed
    Score: 0.004
  257. Closing the Cancer Divide Through Ubuntu: Information and Communication Technology-Powered Models for Global Radiation Oncology. Int J Radiat Oncol Biol Phys. 2016 Mar 01; 94(3):440-9.
    View in: PubMed
    Score: 0.004
  258. Molecular Subtype-Specific Expression of MicroRNA-29c in Breast Cancer Is Associated with CpG Dinucleotide Methylation of the Promoter. PLoS One. 2015; 10(11):e0142224.
    View in: PubMed
    Score: 0.004
  259. Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies. Blood. 1995 Sep 01; 86(5):1931-8.
    View in: PubMed
    Score: 0.004
  260. Mutation spectrum and risk of colorectal cancer in African American families with Lynch syndrome. Gastroenterology. 2015 Nov; 149(6):1446-53.
    View in: PubMed
    Score: 0.004
  261. Construction of a 2.8-megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor suppressor region on 9p21. Proc Natl Acad Sci U S A. 1995 Jul 03; 92(14):6489-93.
    View in: PubMed
    Score: 0.004
  262. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. JAMA Oncol. 2015 Jun; 1(3):306-13.
    View in: PubMed
    Score: 0.004
  263. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol. 2016 05; 141(2):386-401.
    View in: PubMed
    Score: 0.004
  264. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res. 2015 Apr 25; 17:61.
    View in: PubMed
    Score: 0.004
  265. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015 Apr 07; 313(13):1347-61.
    View in: PubMed
    Score: 0.004
  266. Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization. Cancer Res. 1995 Mar 01; 55(5):984-8.
    View in: PubMed
    Score: 0.004
  267. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 01; 21(13):2911-5.
    View in: PubMed
    Score: 0.004
  268. ß-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells. PLoS One. 2015; 10(2):e0117097.
    View in: PubMed
    Score: 0.004
  269. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet. 2015 Feb; 47(2):164-71.
    View in: PubMed
    Score: 0.004
  270. Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo. Target Oncol. 2015 Dec; 10(4):501-8.
    View in: PubMed
    Score: 0.004
  271. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2014 Dec 31; 16(6):3416.
    View in: PubMed
    Score: 0.004
  272. Heterogeneity in hormone-receptor status and survival outcomes among women with synchronous and metachronous bilateral breast cancers. Breast. 2015 Apr; 24(2):131-6.
    View in: PubMed
    Score: 0.004
  273. Metformin for primary colorectal cancer prevention in patients with diabetes: a case-control study in a US population. Cancer. 2015 Apr 01; 121(7):1071-8.
    View in: PubMed
    Score: 0.004
  274. National survey of US oncologists' knowledge, attitudes, and practice patterns regarding herb and supplement use by patients with cancer. J Clin Oncol. 2014 Dec 20; 32(36):4095-101.
    View in: PubMed
    Score: 0.004
  275. Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer models. Cancer Res. 2014 Dec 15; 74(24):7406-17.
    View in: PubMed
    Score: 0.004
  276. Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2015 Jan; 24(1):308-16.
    View in: PubMed
    Score: 0.004
  277. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014 Nov; 148(2):397-406.
    View in: PubMed
    Score: 0.004
  278. Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility. Genet Med. 2015 Jun; 17(6):485-92.
    View in: PubMed
    Score: 0.004
  279. Alcohol consumption and breast cancer risk among women in three sub-Saharan African countries. PLoS One. 2014; 9(9):e106908.
    View in: PubMed
    Score: 0.004
  280. Relationships between computer-extracted mammographic texture pattern features and BRCA1/2 mutation status: a cross-sectional study. Breast Cancer Res. 2014; 16(4):424.
    View in: PubMed
    Score: 0.004
  281. Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014 Jul; 146(2):421-7.
    View in: PubMed
    Score: 0.004
  282. A comprehensive examination of breast cancer risk loci in African American women. Hum Mol Genet. 2014 Oct 15; 23(20):5518-26.
    View in: PubMed
    Score: 0.004
  283. Homozygous deletions within chromosomal bands 9p21-22 in bladder cancer. Cancer Res. 1994 Apr 15; 54(8):2060-3.
    View in: PubMed
    Score: 0.004
  284. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet. 2014 04; 10(4):e1004256.
    View in: PubMed
    Score: 0.004
  285. Building capacity for sustainable research programmes for cancer in Africa. Nat Rev Clin Oncol. 2014 May; 11(5):251-9.
    View in: PubMed
    Score: 0.004
  286. Pilot study demonstrating potential association between breast cancer image-based risk phenotypes and genomic biomarkers. Med Phys. 2014 Mar; 41(3):031917.
    View in: PubMed
    Score: 0.004
  287. Breast cancer detected on an incident (second or subsequent) round of screening MRI: MRI features of false-negative cases. AJR Am J Roentgenol. 2013 Nov; 201(5):1155-63.
    View in: PubMed
    Score: 0.004
  288. The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation. Breast Cancer Res Treat. 2013 Nov; 142(1):177-85.
    View in: PubMed
    Score: 0.004
  289. Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. J Natl Cancer Inst. 2013 Sep 18; 105(18):1365-72.
    View in: PubMed
    Score: 0.004
  290. Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis. Clin Exp Metastasis. 2014 Jan; 31(1):33-45.
    View in: PubMed
    Score: 0.004
  291. Expression of polycomb targets predicts breast cancer prognosis. Mol Cell Biol. 2013 Oct; 33(19):3951-61.
    View in: PubMed
    Score: 0.004
  292. Risk factors for pregnancy-associated breast cancer: a report from the Nigerian Breast Cancer Study. Ann Epidemiol. 2013 Sep; 23(9):551-7.
    View in: PubMed
    Score: 0.004
  293. MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency. Tumour Biol. 2013 Dec; 34(6):3945-58.
    View in: PubMed
    Score: 0.004
  294. Regulation of Tcf7l1 DNA binding and protein stability as principal mechanisms of Wnt/ß-catenin signaling. Cell Rep. 2013 Jul 11; 4(1):1-9.
    View in: PubMed
    Score: 0.004
  295. Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers. Cancer Res. 1993 May 15; 53(10 Suppl):2410-5.
    View in: PubMed
    Score: 0.004
  296. A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat. 2013 May; 139(1):145-53.
    View in: PubMed
    Score: 0.004
  297. A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet. 2013 Jun; 45(6):690-6.
    View in: PubMed
    Score: 0.004
  298. Treatment of cancer in sub-Saharan Africa. Lancet Oncol. 2013 Apr; 14(4):e158-67.
    View in: PubMed
    Score: 0.004
  299. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 2013; 9(3):e1003212.
    View in: PubMed
    Score: 0.004
  300. Relationship between household air pollution from biomass smoke exposure, and pulmonary dysfunction, oxidant-antioxidant imbalance and systemic inflammation in rural women and children in Nigeria. Glob J Health Sci. 2013 Mar 18; 5(4):28-38.
    View in: PubMed
    Score: 0.004
  301. Fine mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers. Carcinogenesis. 2013 Jul; 34(7):1520-8.
    View in: PubMed
    Score: 0.004
  302. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013 Jun 01; 19(11):2817-23.
    View in: PubMed
    Score: 0.004
  303. Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiol Biomarkers Prev. 2013 Apr; 22(4):508-16.
    View in: PubMed
    Score: 0.004
  304. Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? Breast Cancer Res Treat. 2013 Feb; 138(1):273-9.
    View in: PubMed
    Score: 0.004
  305. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun. 2013; 4:1393.
    View in: PubMed
    Score: 0.004
  306. Genome-wide profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer. Nat Commun. 2013; 4:1449.
    View in: PubMed
    Score: 0.004
  307. MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. Breast Cancer Res Treat. 2013 Jan; 137(2):373-82.
    View in: PubMed
    Score: 0.004
  308. Clinical, morphologic, and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia. Blood. 1992 Dec 01; 80(11):2873-82.
    View in: PubMed
    Score: 0.004
  309. Classification of breast lesions pre-contrast injection using water resonance lineshape analysis. NMR Biomed. 2013 May; 26(5):569-77.
    View in: PubMed
    Score: 0.004
  310. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol. 2012 Dec 20; 30(36):4584-6; author reply 4588-9.
    View in: PubMed
    Score: 0.004
  311. Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Mol Oncol. 2013 Jun; 7(3):359-68.
    View in: PubMed
    Score: 0.004
  312. The academic health center in complex humanitarian emergencies: lessons learned from the 2010 Haiti earthquake. Acad Med. 2012 Nov; 87(11):1609-15.
    View in: PubMed
    Score: 0.004
  313. Computerized analysis of mammographic parenchymal patterns on a large clinical dataset of full-field digital mammograms: robustness study with two high-risk datasets. J Digit Imaging. 2012 Oct; 25(5):591-8.
    View in: PubMed
    Score: 0.004
  314. Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia. Genomics. 1992 Oct; 14(2):437-43.
    View in: PubMed
    Score: 0.004
  315. A genome-wide association study of breast cancer in women of African ancestry. Hum Genet. 2013 Jan; 132(1):39-48.
    View in: PubMed
    Score: 0.004
  316. Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes. Leuk Lymphoma. 2013 Jan; 54(1):28-35.
    View in: PubMed
    Score: 0.004
  317. A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2012 Aug; 21(8):1362-70.
    View in: PubMed
    Score: 0.004
  318. ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn. 2012 Jul; 14(4):357-66.
    View in: PubMed
    Score: 0.003
  319. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012 Sep 10; 30(26):3242-9.
    View in: PubMed
    Score: 0.003
  320. Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas. Cancer Res. 1992 May 01; 52(9):2523-9.
    View in: PubMed
    Score: 0.003
  321. Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2012 Sep; 48(9):887-92.
    View in: PubMed
    Score: 0.003
  322. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol. 2012 Apr 20; 30(12):1321-8.
    View in: PubMed
    Score: 0.003
  323. Genetic susceptibility to type 2 diabetes and breast cancer risk in women of European and African ancestry. Cancer Epidemiol Biomarkers Prev. 2012 Mar; 21(3):552-6.
    View in: PubMed
    Score: 0.003
  324. When parents disclose BRCA1/2 test results: their communication and perceptions of offspring response. Cancer. 2012 Jul 01; 118(13):3417-25.
    View in: PubMed
    Score: 0.003
  325. DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy. Mol Carcinog. 2012 Oct; 51 Suppl 1:E83-93.
    View in: PubMed
    Score: 0.003
  326. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012 Apr; 132(3):1049-62.
    View in: PubMed
    Score: 0.003
  327. Lack of association between common single nucleotide polymorphisms in the TERT-CLPTM1L locus and breast cancer in women of African ancestry. Breast Cancer Res Treat. 2012 Feb; 132(1):341-5.
    View in: PubMed
    Score: 0.003
  328. Clinical implications of ERß methylation on sporadic breast cancers in Chinese women. Med Oncol. 2012 Sep; 29(3):1569-75.
    View in: PubMed
    Score: 0.003
  329. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat. 2012 Jun; 133(3):865-80.
    View in: PubMed
    Score: 0.003
  330. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2011; 13(6):R110.
    View in: PubMed
    Score: 0.003
  331. Clinicopathological significance and prognostic value of Xeroderma pigmentosum complementary group C (XPC) expression in sporadic breast cancer patients. Med Oncol. 2012 Sep; 29(3):1543-53.
    View in: PubMed
    Score: 0.003
  332. Non-contrast enhanced MRI for evaluation of breast lesions: comparison of non-contrast enhanced high spectral and spatial resolution (HiSS) images versus contrast enhanced fat-suppressed images. Acad Radiol. 2011 Dec; 18(12):1467-74.
    View in: PubMed
    Score: 0.003
  333. Clinical significance of KISS1 protein expression for brain invasion and metastasis. Cancer. 2012 Apr 15; 118(8):2096-105.
    View in: PubMed
    Score: 0.003
  334. Lack of association between common UGT2B nonsynonymous single-nucleotide polymorphisms and breast cancer in populations of African ancestry. Int J Cancer. 2012 Jun 01; 130(11):2740-2.
    View in: PubMed
    Score: 0.003
  335. Atopy is associated with asthma in adults living in rural and urban southwestern Nigeria. J Asthma. 2011 Nov; 48(9):894-900.
    View in: PubMed
    Score: 0.003
  336. Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Res. 2011 Sep 01; 71(17):5792-805.
    View in: PubMed
    Score: 0.003
  337. Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nat Med. 2011 Jul 24; 17(8):941-3.
    View in: PubMed
    Score: 0.003
  338. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer. 2012 Feb 15; 118(4):908-13.
    View in: PubMed
    Score: 0.003
  339. Performance of Lynch syndrome predictive models in a multi-center US referral population. Am J Gastroenterol. 2011 Oct; 106(10):1822-7; quiz 1828.
    View in: PubMed
    Score: 0.003
  340. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011 Jul 01; 12(1):9-46.
    View in: PubMed
    Score: 0.003
  341. Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers. Cancer Epidemiol Biomarkers Prev. 2011 Aug; 20(8):1690-702.
    View in: PubMed
    Score: 0.003
  342. A signature of balancing selection in the region upstream to the human UGT2B4 gene and implications for breast cancer risk. Hum Genet. 2011 Dec; 130(6):767-75.
    View in: PubMed
    Score: 0.003
  343. Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Hum Genet. 2011 Nov; 130(5):685-99.
    View in: PubMed
    Score: 0.003
  344. Malignant effusions. CA Cancer J Clin. 1991 May-Jun; 41(3):166-79.
    View in: PubMed
    Score: 0.003
  345. Differential allelic expression of c.1568C > A at UGT2B15 is due to variation in a novel cis-regulatory element in the 3'UTR. Gene. 2011 Jul 15; 481(1):24-8.
    View in: PubMed
    Score: 0.003
  346. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2011 Apr 26; 104(9):1384-92.
    View in: PubMed
    Score: 0.003
  347. Germline mutational analysis of the C19orf62 gene in African-American women with breast cancer. Breast Cancer Res Treat. 2011 Jun; 127(3):871-7.
    View in: PubMed
    Score: 0.003
  348. Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2011 May; 20(5):1032-8.
    View in: PubMed
    Score: 0.003
  349. SNP discovery, expression and cis-regulatory variation in the UGT2B genes. Pharmacogenomics J. 2012 Aug; 12(4):287-96.
    View in: PubMed
    Score: 0.003
  350. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2011 May; 127(1):287-96.
    View in: PubMed
    Score: 0.003
  351. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res. 2010 Dec 01; 70(23):9742-54.
    View in: PubMed
    Score: 0.003
  352. Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. J Med Genet. 2011 Jan; 48(1):64-8.
    View in: PubMed
    Score: 0.003
  353. Characterizing early contrast uptake of ductal carcinoma in situ with high temporal resolution dynamic contrast-enhanced MRI of the breast: a pilot study. Phys Med Biol. 2010 Oct 07; 55(19):N473-85.
    View in: PubMed
    Score: 0.003
  354. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat. 2011 Aug; 128(3):703-711.
    View in: PubMed
    Score: 0.003
  355. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010 Sep 01; 304(9):967-75.
    View in: PubMed
    Score: 0.003
  356. Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus. PLoS Genet. 2010 Jul 22; 6(7):e1001029.
    View in: PubMed
    Score: 0.003
  357. Parent opinions regarding the genetic testing of minors for BRCA1/2. J Clin Oncol. 2010 Jul 20; 28(21):3498-505.
    View in: PubMed
    Score: 0.003
  358. Echo-planar spectroscopic imaging (EPSI) of the water resonance structure in human breast using sensitivity encoding (SENSE). Magn Reson Med. 2010 Jun; 63(6):1557-63.
    View in: PubMed
    Score: 0.003
  359. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2010 Jul 10; 28(20):3336-43.
    View in: PubMed
    Score: 0.003
  360. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol. 2010 Jun; 176(6):2911-20.
    View in: PubMed
    Score: 0.003
  361. rs2981582 is associated with FGFR2 expression in normal breast. Cancer Genet Cytogenet. 2010 Mar; 197(2):193-4.
    View in: PubMed
    Score: 0.003
  362. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat. 2010 Nov; 124(1):195-203.
    View in: PubMed
    Score: 0.003
  363. Long-term survival of patients with intermediate and high grade lymphoma treated with COMLA/ABP. Leukemia. 1990 Feb; 4(2):127-31.
    View in: PubMed
    Score: 0.003
  364. Allelic imbalance (AI) identifies novel tissue-specific cis-regulatory variation for human UGT2B15. Hum Mutat. 2010 Jan; 31(1):99-107.
    View in: PubMed
    Score: 0.003
  365. The expanding use of third-generation aromatase inhibitors: what the general internist needs to know. J Gen Intern Med. 2009 Nov; 24 Suppl 2:S383-8.
    View in: PubMed
    Score: 0.003
  366. Cancer survivorship care: exploring the role of the general internist. J Gen Intern Med. 2009 Nov; 24 Suppl 2:S495-500.
    View in: PubMed
    Score: 0.003
  367. Fourier component imaging of water resonance in the human breast provides markers for malignancy. Phys Med Biol. 2009 Oct 07; 54(19):5767-79.
    View in: PubMed
    Score: 0.003
  368. Clinical implementation of a multislice high spectral and spatial resolution-based MRI sequence to achieve unilateral full-breast coverage. Magn Reson Imaging. 2010 Jan; 28(1):16-21.
    View in: PubMed
    Score: 0.003
  369. Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Cancer Res. 2009 Jul 15; 69(14):5801-10.
    View in: PubMed
    Score: 0.003
  370. A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med. 2009 Mar 16; 7:9.
    View in: PubMed
    Score: 0.003
  371. Learning of your parent's BRCA mutation during adolescence or early adulthood: a study of offspring experiences. Psychooncology. 2009 Feb; 18(2):200-8.
    View in: PubMed
    Score: 0.003
  372. Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Res. 2009; 11(5):R76.
    View in: PubMed
    Score: 0.003
  373. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
    View in: PubMed
    Score: 0.003
  374. Glucocorticoid receptor expression in breast cancer associates with older patient age. Breast Cancer Res Treat. 2009 Aug; 116(3):441-7.
    View in: PubMed
    Score: 0.003
  375. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer. 2008 Jul 22; 99(2):371-4.
    View in: PubMed
    Score: 0.003
  376. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet. 2008 Jun; 40(6):703-6.
    View in: PubMed
    Score: 0.003
  377. Genomewide scan for loss of heterozygosity and chromosomal amplification in breast carcinoma using single-nucleotide polymorphism arrays. Cancer Genet Cytogenet. 2008 Apr 15; 182(2):69-74.
    View in: PubMed
    Score: 0.003
  378. Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol Syst Biol. 2008; 4:188.
    View in: PubMed
    Score: 0.003
  379. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet. 2008 Apr; 82(4):937-48.
    View in: PubMed
    Score: 0.003
  380. Should genetic testing for BRCA1/2 be permitted for minors? Opinions of BRCA mutation carriers and their adult offspring. Am J Med Genet C Semin Med Genet. 2008 Feb 15; 148C(1):70-7.
    View in: PubMed
    Score: 0.003
  381. Genetic variation in IGFBP2 and IGFBP5 is associated with breast cancer in populations of African descent. Hum Genet. 2008 Apr; 123(3):247-55.
    View in: PubMed
    Score: 0.003
  382. Power spectral analysis of mammographic parenchymal patterns for breast cancer risk assessment. J Digit Imaging. 2008 Jun; 21(2):145-52.
    View in: PubMed
    Score: 0.003
  383. RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. Cancer Res. 2008 Jan 01; 68(1):22-5.
    View in: PubMed
    Score: 0.003
  384. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer. 2007 Dec 15; 121(12):2661-7.
    View in: PubMed
    Score: 0.003
  385. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008 Jan; 108(1):3-9.
    View in: PubMed
    Score: 0.003
  386. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet. 2007 Dec; 81(6):1186-200.
    View in: PubMed
    Score: 0.003
  387. Early-life conditions and mechanisms of population health vulnerabilities. Health Aff (Millwood). 2007 Sep-Oct; 26(5):1238-48.
    View in: PubMed
    Score: 0.003
  388. How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults. J Clin Oncol. 2007 Aug 20; 25(24):3705-11.
    View in: PubMed
    Score: 0.003
  389. AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev. 2007 Jul; 16(7):1416-21.
    View in: PubMed
    Score: 0.002
  390. Fractal analysis of mammographic parenchymal patterns in breast cancer risk assessment. Acad Radiol. 2007 May; 14(5):513-21.
    View in: PubMed
    Score: 0.002
  391. X-ray fluorescence microscopy reveals large-scale relocalization and extracellular translocation of cellular copper during angiogenesis. Proc Natl Acad Sci U S A. 2007 Feb 13; 104(7):2247-52.
    View in: PubMed
    Score: 0.002
  392. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007; 8(5):R76.
    View in: PubMed
    Score: 0.002
  393. Fat suppression with spectrally selective inversion vs. high spectral and spatial resolution MRI of breast lesions: qualitative and quantitative comparisons. J Magn Reson Imaging. 2006 Dec; 24(6):1311-5.
    View in: PubMed
    Score: 0.002
  394. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med. 2006 Dec; 3(12):e486.
    View in: PubMed
    Score: 0.002
  395. The I1307K APC polymorphism in Ashkenazi Jews with colorectal cancer: clinical and pathologic features. Cancer Genet Cytogenet. 2006 Aug; 169(1):33-8.
    View in: PubMed
    Score: 0.002
  396. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006 Jul 12; 296(2):185-92.
    View in: PubMed
    Score: 0.002
  397. "Why take it if you don't have anything?" breast cancer risk perceptions and prevention choices at a public hospital. J Gen Intern Med. 2006 Jul; 21(7):779-85.
    View in: PubMed
    Score: 0.002
  398. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006 May 01; 118(9):2281-4.
    View in: PubMed
    Score: 0.002
  399. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006 Apr 27; 7:96.
    View in: PubMed
    Score: 0.002
  400. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006 Jun 01; 24(16):2437-43.
    View in: PubMed
    Score: 0.002
  401. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res. 2006; 8(2):R23.
    View in: PubMed
    Score: 0.002
  402. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res. 2006; 8(2):R15.
    View in: PubMed
    Score: 0.002
  403. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol. 2006 Mar; 7(3):223-9.
    View in: PubMed
    Score: 0.002
  404. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006 Feb; 19(2):264-71.
    View in: PubMed
    Score: 0.002
  405. High spectral and spatial resolution MRI of breast lesions: preliminary clinical experience. AJR Am J Roentgenol. 2006 Jan; 186(1):30-7.
    View in: PubMed
    Score: 0.002
  406. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer. 2005 Dec 20; 117(6):988-91.
    View in: PubMed
    Score: 0.002
  407. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005 Nov 01; 23(31):7804-10.
    View in: PubMed
    Score: 0.002
  408. Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control. 2005 Aug; 16(6):667-74.
    View in: PubMed
    Score: 0.002
  409. Computerized texture analysis of mammographic parenchymal patterns of digitized mammograms. Acad Radiol. 2005 Jul; 12(7):863-73.
    View in: PubMed
    Score: 0.002
  410. A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomarkers Prev. 2005 Jun; 14(6):1534-8.
    View in: PubMed
    Score: 0.002
  411. Phenotypic heterogeneity in multiple myeloma families. J Clin Oncol. 2005 Feb 01; 23(4):685-93.
    View in: PubMed
    Score: 0.002
  412. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005 Jan; 96(1):222-6.
    View in: PubMed
    Score: 0.002
  413. Chromosome band 16q22-linked familial AML: exclusion of candidate genes, and possible disease risk modification by NQO1 polymorphisms. Genes Chromosomes Cancer. 2004 Nov; 41(3):278-82.
    View in: PubMed
    Score: 0.002
  414. Fourier components of inhomogeneously broadened water resonances in breast: a new source of MRI contrast. Magn Reson Med. 2004 Jul; 52(1):193-6.
    View in: PubMed
    Score: 0.002
  415. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004 Jun 15; 22(12):2328-35.
    View in: PubMed
    Score: 0.002
  416. No evidence for core-binding factor CBFbeta as a leukemia predisposing factor in chromosome 16q22-linked familial AML. Leukemia. 2004 Apr; 18(4):881.
    View in: PubMed
    Score: 0.002
  417. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res. 2004 Mar 15; 10(6):2029-34.
    View in: PubMed
    Score: 0.002
  418. Computerized analysis of mammographic parenchymal patterns for assessing breast cancer risk: effect of ROI size and location. Med Phys. 2004 Mar; 31(3):549-55.
    View in: PubMed
    Score: 0.002
  419. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004 Mar 15; 22(6):1055-62.
    View in: PubMed
    Score: 0.002
  420. MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res. 2004 Jan 15; 10(2):499-507.
    View in: PubMed
    Score: 0.002
  421. The effect of varying spectral resolution on the quality of high spectral and spatial resolution magnetic resonance images of the breast. J Magn Reson Imaging. 2003 Oct; 18(4):442-8.
    View in: PubMed
    Score: 0.002
  422. EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer. Oncogene. 2003 Aug 07; 22(32):5070-81.
    View in: PubMed
    Score: 0.002
  423. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2002 Dec 04; 94(23):1773-9.
    View in: PubMed
    Score: 0.002
  424. Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers. Radiology. 2002 Nov; 225(2):519-26.
    View in: PubMed
    Score: 0.002
  425. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst. 2002 Jun 05; 94(11):844-51.
    View in: PubMed
    Score: 0.002
  426. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002 May 23; 346(21):1616-22.
    View in: PubMed
    Score: 0.002
  427. Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope. 2002 Mar; 112(3):472-81.
    View in: PubMed
    Score: 0.002
  428. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics. 2001 Oct; 11(7):635-8.
    View in: PubMed
    Score: 0.002
  429. Identification of a 1.2 Kb cDNA fragment from a region on 9p21 commonly deleted in multiple tumor types. Cancer Genet Cytogenet. 2001 Sep; 129(2):93-101.
    View in: PubMed
    Score: 0.002
  430. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol. 2000 Oct 01; 18(19):3360-9.
    View in: PubMed
    Score: 0.002
  431. Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in patients with previously resected colon polyps and first degree female relatives of breast cancer patients. Clin Cancer Res. 2000 Oct; 6(10):3870-7.
    View in: PubMed
    Score: 0.002
  432. Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression. Clin Cancer Res. 2000 Oct; 6(10):4043-8.
    View in: PubMed
    Score: 0.002
  433. Evidence of a founder BRCA1 mutation in Scotland. Br J Cancer. 2000 Feb; 82(3):705-11.
    View in: PubMed
    Score: 0.001
  434. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet. 1999 Nov 27; 354(9193):1846-50.
    View in: PubMed
    Score: 0.001
  435. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999 Sep 01; 91(17):1475-9.
    View in: PubMed
    Score: 0.001
  436. Lack of evidence for a polymorphism at codon 160 of human O6-alkylguanine-DNA alkyltransferase gene in normal tissue and cancer. Clin Cancer Res. 1999 Jan; 5(1):209-13.
    View in: PubMed
    Score: 0.001
  437. Therapeutic plasma exchange for the acute management of the catastrophic antiphospholipid syndrome: beta(2)-glycoprotein I antibodies as a marker of response to therapy. J Clin Apher. 1999; 14(4):171-6.
    View in: PubMed
    Score: 0.001
  438. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998 Jul; 16(7):2417-25.
    View in: PubMed
    Score: 0.001
  439. Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst. 1998 May 20; 90(10):761-6.
    View in: PubMed
    Score: 0.001
  440. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. Hum Mutat. 1998; 12(4):289.
    View in: PubMed
    Score: 0.001
  441. Expression of methylthioadenosine phosphorylase cDNA in p16-, MTAP- malignant cells: restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis. Mol Pharmacol. 1997 Nov; 52(5):903-11.
    View in: PubMed
    Score: 0.001
  442. The American Society of Clinical Oncology position on genetic testing: implications for health care providers: workshop no. 4. Cancer. 1997 Aug 01; 80(3 Suppl):632-4.
    View in: PubMed
    Score: 0.001
  443. Report on the Fifth International Workshop on Chromosome 9 held at Eynsham, Oxfordshire, UK, September 4-6, 1996. Ann Hum Genet. 1997 May; 61(Pt 3):183-206.
    View in: PubMed
    Score: 0.001
  444. Preferential loss of expression of p16(INK4a) rather than p19(ARF) in breast cancer. Clin Cancer Res. 1996 Dec; 2(12):1993-8.
    View in: PubMed
    Score: 0.001
  445. CDKN2 gene deletion is not found in chronic lymphoid leukaemias of B- and T-cell origin but is frequent in acute lymphoblastic leukaemia. Br J Haematol. 1995 Dec; 91(4):865-70.
    View in: PubMed
    Score: 0.001
  446. Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent. Clin Cancer Res. 1995 Oct; 1(10):1133-8.
    View in: PubMed
    Score: 0.001
  447. Detection of 9p deletions in leukemia cell lines by interphase fluorescence in situ hybridization with YAC-derived probes. Cancer Genet Cytogenet. 1995 Aug; 83(1):46-55.
    View in: PubMed
    Score: 0.001
  448. Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res. 1995 Feb 01; 55(3):493-7.
    View in: PubMed
    Score: 0.001
  449. Mapping a putative tumor suppressor gene on chromosome 9 bands p21-p22 with microdissection probes. Genomics. 1994 Nov 15; 24(2):211-7.
    View in: PubMed
    Score: 0.001
  450. Breakpoint junctions of chromosome 9p deletions in two human glioma cell lines. Mol Cell Biol. 1994 Nov; 14(11):7604-10.
    View in: PubMed
    Score: 0.001
  451. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 1994 Nov 01; 54(21):5547-51.
    View in: PubMed
    Score: 0.001
  452. Analysis of tumor suppressor gene on human chromosome 9 in mouse x human somatic cell hybrids. Somat Cell Mol Genet. 1994 Sep; 20(5):391-400.
    View in: PubMed
    Score: 0.001
  453. Structure of the human type-I interferon gene cluster determined from a YAC clone contig. Genomics. 1994 Aug; 22(3):540-52.
    View in: PubMed
    Score: 0.001
  454. Distinct deletions of chromosome 9p associated with melanoma versus glioma, lung cancer, and leukemia. Cancer Res. 1994 Jan 15; 54(2):344-8.
    View in: PubMed
    Score: 0.001
  455. Methylthioadenosine phosphorylase deficiency in human non-small cell lung cancers. Cancer Res. 1993 Mar 01; 53(5):1098-101.
    View in: PubMed
    Score: 0.001
  456. Correlation of cytogenetic analysis and loss of heterozygosity studies in human diffuse astrocytomas and mixed oligo-astrocytomas. Genes Chromosomes Cancer. 1992 Nov; 5(4):357-74.
    View in: PubMed
    Score: 0.001
  457. Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11). Genes Chromosomes Cancer. 1990 Jul; 2(2):147-58.
    View in: PubMed
    Score: 0.001
  458. Gastric adenocarcinoma presenting with soft tissue masses. Am J Gastroenterol. 1990 Jan; 85(1):76-7.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.